Maxim Group started coverage on shares of GW Pharmaceuticals PLC- (NASDAQ:GWPH) in a report released on Thursday. The brokerage issued a buy rating and a $135.00 price objective on the biopharmaceutical company’s stock.
“Epilepsy remains a challenging indication to treat, with over a third of patients (750k patients in the U.S.) who are inadequately controlled despite several antiepileptic drugs (market of $5B) taken concurrently. GW’s lead product, Epidiolex, an orphan drug designated oral CBD (cannabidiol), showed positive results in three P3 trials for Dravet (DS) and Lennox-Gastaut syndromes (LGS).”,” the firm’s analyst wrote.
Other analysts also recently issued research reports about the stock. Cowen and Company set a $135.00 target price on shares of GW Pharmaceuticals PLC- and gave the company a buy rating in a research report on Monday, February 6th. Cantor Fitzgerald set a $208.00 target price on shares of GW Pharmaceuticals PLC-